Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells

BACKGROUND: BRAF inhibitors, such as vemurafenib, have shown efficacy in BRAF-mutant melanoma treatment but acquired-resistance invariably develops. Unveiling the potential vulnerabilities associated with vemurafenib resistance could provide rational strategies for combinatorial treatment. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado-Goñi, Teresa, Galobart, Teresa Casals, Wantuch, Slawomir, Normantaite, Deimante, Leach, Martin O., Whittaker, Steven R., Beloueche-Babari, Mounia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964672/
https://www.ncbi.nlm.nih.gov/pubmed/31819183
http://dx.doi.org/10.1038/s41416-019-0628-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964672/
https://www.ncbi.nlm.nih.gov/pubmed/31819183
http://dx.doi.org/10.1038/s41416-019-0628-x

Ejemplares similares